Dosing & Uses
Dosage Forms & Strengths
Indicated for treatment of community-acquired pneumonia due to Streptococcus pneumoniae, (including multi-drug resistant isolates), Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, or Mycoplasma pneumoniae
800 mg PO qDay for 7-10 days
Renal impairment (CrCl <30 mL/min): 600 mg PO qDay
Renal impairment (CrCl <30 mL/min) and hepatic impairment: 400 mg PO qDay
Severe renal impairment (dialysis dependent): 600 mg PO administered 2 hr postdialysis
May take with or without food
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Exacerbation of myasthenia gravis
Ventricular arrhythmias with fatal outcome, ischemic cardiac events in the context of hypersensitivity reactions
Black Box Warnings
Fatal and life-threatening respiratory failure have been reported in patients with myasthenia gravis who were treated with this drug
Hypersensitivity to telithromycin or any macrolide antibiotic
Concomitant administration with cisapride, pimozide, astemizole, terfenadine, ergot alkaloids
Coadministration of colchicine with telithromycin in patients with renal/hepatic impairment
May prolong QT interval
Avoid coadministration with colchicine; if telithromycin is prescribed in patients with normal renal/hepatic function, decrease the dose of colchicine
Cases of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, reported
Risk of C. difficile pseudomembranous colitis
Risk of serious hepatotoxicity
Risk of visual disturbances & LOC
Pregnancy & Lactation
Pregnancy Category: B
Lactation: may be excreted in breast milk, use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Ketolide antibiotic (related to macrolides); suppresses protein synthesis by binding to bacterial 50S ribosomal subunit, and inhibits assembly of new bacterial ribosomes.
Peak Plasma Time: 1 hr
Protein Bound: 60-70%
Vd: 2.9 L/kg
Hepatic P450 enzyme CYP3A4
Enzymes inhibited: CYP3A4; CYP2D6 (mild)
Half-life: 10 hr
Excretion: urine, bile
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.